⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MOLN News
Molecular Partners AG American Depositary Shares
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
globenewswire.com
MOLN
Molecular Partners gibt Finanzergebnisse für das erste Halbjahr 2026 und wichtige Unternehmensentwicklungen bekannt: DLL3-Radiotherapie-Kandidat MP0712 erreicht in der Phase-1/2a-Studie die nächsthöhere Dosisstufe
globenewswire.com
MOLN
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
globenewswire.com
MOLN
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
globenewswire.com
MOLN
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
globenewswire.com
MOLN
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
globenewswire.com
MOLN
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
globenewswire.com
MOLN
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
globenewswire.com
MOLN
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
KURA
BMY
IPHA
MRK
MNPR
JAZZ
MOLN
LLY
GSK
AGEN
PFE
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
globenewswire.com
MOLN